title: Anti-CD3 and anti-CD2-induced T-cell activation in primary Sjögren's syndrome.
abstract: Because T-cell dysfunctions have been reported in patients with primary Sjögren's syndrome (SS), peripheral blood mononuclear cell (PBMC) proliferation obtained with anti-CD3 and anti-CD2 monoclonal antibodies was evaluated in these patients. Anti-CD3-induced mitogenesis, which varied widely among the patients, was lower in subjects with evidence of anti-SSA and anti-SSB antibodies than in controls. Moreover, the anti-CD2-induced response was depressed in about half the patients and the nonresponders were mainly those with anti-SSA and anti-SSB antibodies. Phorbol myristate acetate, a protein kinase C activator, used alone or added to anti-CD3, induced greater proliferation in patients than in control PBMC. In contrast, exogenous recombinant interleukin 2 (rIL-2) did not significantly enhance the anti-CD2-induced response of patients' PBMC, as it did in normal PBMC. Peripheral blood and parotid T cells from a patient with well-defined primary SS and parotid enlargement also responded poorly to anti-CD2 stimulation. Exogenous rIL-2 restored T-cell proliferation only in the salivary gland cultures of this patient. The present findings suggest that there is a T-cell activation defect in subjects with primary SS, particularly in those with circulating anti-SSA and anti-SSB antibodies. In addition, the difference in the response to IL-2 of peripheral blood and parotid-infiltrating T cells would seem to indicate that T-cell subsets are differently distributed in the blood and inflammation site.
authors.affiliation: Department of Internal Medicine, University of Perugia, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Gerli
authors.forename: A
authors.initials: A
authors.lastname: Bertotto
authors.forename: C
authors.initials: C
authors.lastname: Cernetti
authors.forename: E
authors.initials: E
authors.lastname: Agea
authors.forename: S
authors.initials: S
authors.lastname: Crupi
authors.forename: C
authors.initials: C
authors.lastname: Arcangeli
authors.forename: F
authors.initials: F
authors.lastname: Spinozzi
authors.forename: R
authors.initials: R
authors.lastname: Galandrini
authors.forename: P
authors.initials: P
authors.lastname: Rambotti
mesh_terms: D000328:Adult; D000974:Antibodies, Antinuclear; D000911:Antibodies, Monoclonal; D000945:Antigens, Differentiation, T-Lymphocyte; D018801:CD2 Antigens; D017252:CD3 Complex; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D011948:Receptors, Antigen, T-Cell; D011971:Receptors, Immunologic; D012859:Sjogren's Syndrome / Q000276:immunology*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
chemical_list: D000974:Antibodies, Antinuclear; D000911:Antibodies, Monoclonal; D000945:Antigens, Differentiation, T-Lymphocyte; D018801:CD2 Antigens; D017252:CD3 Complex; D007376:Interleukin-2; D011948:Receptors, Antigen, T-Cell; D011971:Receptors, Immunologic; C035356:SS-A antibodies; C035357:SS-B antibodies; D013755:Tetradecanoylphorbol Acetate